Slater Fund offers 0000 for new drug-discovery firm

PROVIDENCE, R.I. — The Slater Technology Fund on Thursday announced it is dedicating $500,000 in seed funding to help launch MindImmune Therapeutics, a company that hopes to develop drugs that will utilize the immune system to treat such neurological diseases as Alzheimer’s and Huntington’s. The money will further expand the company’s collaboration with the George and Anne Ryan Institute for Neuroscience at the University of Rhode Island. The university has committed laboratory and office space for the company’s initial operations, and MindImmune’s founders have received adjunct faculty appointments, according to Slater. “The tremendous burden of brain disease in human suffering, its high cost to society and the paucity of new treatments are contributing to an emerging health crisis,” Stevin Zorn, president and CEO of MindImmune, said in a media release.…


Link to Full Article: Slater Fund offers 0000 for new drug-discovery firm